Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
      • Research Guidelines
        • Minimum Information About Microarray Data Experiments (MIAME)
      • Abstract
      • Acknowledgments
      • Clinical Implications (Only by invitation)
      • Conflict(s) of Interest/Disclosure(s) Statement
      • Figure Legends
      • Figures
      • Novelty and Significance: 1) What Is New, 2) What Is Relevant?
      • References
      • Sources of Funding
      • Tables
      • Text
      • Title Page
      • Online/Data Supplement
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
      • Change of Authorship Form
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Hypertension

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Editorial Commentaries

Atrial Peptides Modify the Effect of Marinobufagenin on Sodium Pumps

Implications for Blood Pressure Control

Vardaman M. Buckalew
Download PDF
https://doi.org/10.1161/01.HYP.0000248119.54493.18
Hypertension. 2006;48:1029-1030
Originally published November 16, 2006
Vardaman M. Buckalew
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading

The demonstration that acute volume expansion released a blood borne natriuretic substance initiated a search for “natriuretic hormone.”1 It was initially thought that this factor might regulate blood pressure by regulating blood volume as an endogenous diuretic. Subsequently, it was suggested that natriuretic hormone might be “endogenous digitalis” and cause natriuresis and vasoconstriction by inhibition of renal tubular and vascular Na,K ATPase (NKA), respectively.1 The possibility that this factor might explain the link between sodium intake and hypertension provided an attractive hypothesis, but progress was hampered by difficulties identifying its biochemical structure. “Endogenous digitalis-like factor” has now been identified as multiple cardiotonic steroids of 2 classes, a glycoside indistinguishable from plant derived ouabain and several bufadienolides that are similar if not identical to those found in toads.2 Most of the endogenous cardiotonic steroids that have been studied cause natriuresis; however, none are yet firmly established as natriuretic hormones. On the other hand, endogenous digitalis-like factors have been implicated as causative agents in some experimental and human forms of hypertension, including preeclampsia.1–3 The exact role of the different types of steroids in the various hypertensive states remains to be determined.

By contrast with endogenous digitalis, the natriuretic factors discovered in cardiac atrial granules were rapidly identified as a family of small peptides derived from a larger precursor. Although the precise role of these peptides in plasma volume and blood pressure regulation is still not entirely clear, they inhibit renal tubular sodium reabsorption in multiple sites, and mice in which the precursor gene has been knocked out develop a salt-sensitive type of hypertension.4 Some atrial peptides have been shown to inhibit renal-derived NKA; however, they are clearly distinguished physiologically from digitalis-like factors by their vasodilator and blood pressure–lowering effects.

The fact that plasma volume expansion increases the plasma concentration of 2 classes of natriuretic factors with opposite effects on vascular tone suggests the possibility of some modulating interactions between them. Although this has long been recognized, few previous studies have addressed this question directly. The article by Fedorova et al5 in this issue of Hypertension demonstrates that such an interaction may occur at the cellular level and begins to explore the mechanisms of this potentially important phenomenon. Using normal Sprague–Dawley rats, they studied the interaction between 2 atrial peptides, human ANP and prepro-ANP 104 to 123 and marinobufagenin (MBG), an endogenous bufadienolide that has been shown to inhibit the ouabain-resistant α-1 NKA found in rat renal and vascular tissue. They showed that both ANP analogs and MBG inhibited NKA catalytic activity of microsomes from renal medulla and that these effects were additive. By contrast, in aortic vascular rings and sarcolemma, atrial peptides had no effect or slightly increased NKA activity and completely prevented the inhibitory effect of MBG. To explore the signaling mechanisms that might be involved in this interaction, they focused on the phosphorylation status of the α-1 subunit of NKA.

In the renal medulla preparation, atrial peptides increased phosphorylation of α-1 NKA by a protein kinase G (PKG)–dependent pathway. Previous studies have shown that NKA catalytic activity is reduced by phosphorylation of the α-subunit by protein kinases A and C6; however, the intracellular signaling pathway by which atrial peptide-activated PKG increases NKA phosphorylation is not established. Inhibition of renal NKA by atrial peptides may require dopamine cAMP–regulated phosphoprotein (DARPP-32), because it was blocked by knocking out the gene for this protein.7 DARPP-32 is a major substrate of PKG, and the pathway suggested by these gene knockout studies (Figure) could have caused the effects in renal tissue observed by Fedorova et al.5 It should be noted that this proposed PKG-dependent pathway causes a similar effect on NKA as activation of PKA and PKC, providing an opportunity for cross-talk between the different protein kinases.

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Proposed regulation of NKA activity by phosphorylation-dephosphorylation reactions.7 Phosphorylation of the NKA α subunit by protein kinases A and C (PKA and PKC) produces a less active form of the enzyme. Dephosphorylation by protein phosphatase 1 (PP-I) produces a more active form. Phosphorylation of the dopamine cAMP–regulated phosphoprotein (DARPP-32), by atrial peptide-activated PKG, inhibits PP-I, causing increase of the less active form of NKA, reducing catalytic activity. This pathway provides one opportunity for crosstalk among the 3 protein kinases.

In aortic rings and sarcolemma, by contrast, atrial peptides had no effect or slightly stimulated NKA catalytic activity and reduced phosphorylation of α-1 NKA, again by a PKG-dependent pathway. Interestingly, in the presence of atrial peptides, the effect of MBG on NKA catalytic activity was inhibited, an effect also mediated through a PKG-dependent mechanism. Because the effects on both phosphorylation and catalytic activity were PKG dependent, Fedorova et al5 postulated that the dephosphorylated form of vascular NKA might be less sensitive to inhibition by a specific α-1 inhibitor, MBG. Compatible with this interpretation, previous work by this group had shown that phosphorylation of the α-1 subunit of human vascular NKA by a PKC activator phorbol 12, 13-diacetate caused the opposite effect shown in the present experiments, that is, inhibition of catalytic activity and potentiation of vasoconstriction by MBG.8

The difference in atrial peptide effects on NKA phosphorylation and catalytic activity between vascular and renal tissues could be because of tissue-specific differences in PKG isoforms, as the authors suggest. However, the pathway by which PKG activation in aortic tissue might decrease phosphorylation of NKA remains to be determined. It could, as suggested for renal tissue, involve an interaction between kinases and phosphatases (Figure), but one that increases rather than decreases dephosphorylated NKA.

The role of phosphatases in the regulation of NKA activity was observed in previous studies of another cGMP/PKG agonist, NO. The NO donor sodium nitroprusside stimulated Na pump current in rabbit ventricular myocytes by a mechanism dependent on cGMP/PKG, an effect inhibited by the protein phosphatase-1 and -2A inhibitor okadaic acid.9 In this regard, it would be interesting to determine the effect of okadaic acid on the phenomena observed in vascular tissue by Fedorova et al,5 because the signaling pathway by which NO and atrial peptides alter NKA activity could be similar. This possibility is suggested by the similar pattern of tissue heterogeneity demonstrated by both atrial peptides and NO on NKA activity.10

That hormone-activated protein kinases have opposite effects on NKA activity in different tissues is a well-known phenomenon.10 The current studies, however, suggest a potentially important translation of a specific instance of this phenomenon to the regulation of blood pressure and renal function. Thus, synergism between MBG and atrial peptides in the kidney would obviously facilitate the excretion of a salt load and contribute to the fine regulation of renal sodium excretion. It might also provide an important mechanism to explain the natriuretic effect of atrial peptides in the setting of acute volume expansion that has not been considered previously. In the vasculature, antagonism of the vasoconstrictor effect of MBG by atrial peptides would provide an explanation for how volume expansion might lead to an increase in renal sodium excretion mediated by digitalis-like factors without causing a rise in blood pressure. Conversely, absence of this interaction might lead to a salt-sensitive form of hypertension, such as that found in the atrial peptide precursor knockout mice. Studies of the intracellular signaling pathways that confer organ specificity to the interaction between 2 physiologically important vasoactive classes could lead to a better understanding of the cellular mechanisms underlying various forms of hypertension, especially the salt-sensitive types.

Acknowledgments

Disclosures

None.

Footnotes

  • The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.

References

  1. ↵
    Buckalew VM. Endogenous digitalis-like factors. An historical overview. Front Biosci. 2005; 10: 2325–2334.
    OpenUrlPubMed
  2. ↵
    Schoner W. Endogenous cardiac glycosides, a new class of steroid hormones. Eur J Biochem. 2002; 269: 2440–2448.
    OpenUrlPubMed
  3. ↵
    Dostanic-Larson I, Van Huysse JW, Lorenz JN, Lingrel JB. The highly conserved cardiac glycoside binding site of NA, K-ATPase plays a role in blood pressure regulation. Proc Nat Acad Sci U S A. 2005; 102: 15845–15850.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Melo LG, Steinhelper ME, Pang SC, Tse Y, Ackermann U. ANP in regulation of arterial pressure and fluid-electrolyte balance: lessons from genetic mouse models. Physiol Genomics. 2000; 3: 45–58.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Fedorova OV, Agalakova NI, Morrell CH, Lakatta EG, Bagrov AY. ANP differentially modulates marinobufagenin-induced sodium pump inhibition in kidney and aorta. Hypertension. 2006; 48: 1160–1168.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Aperia A. Regulation of sodium/potassium ATPase activity: impact on salt balance and vascular contractility. Curr Hypertens Rep. 2001; 3: 165–171.
    OpenUrlCrossRefPubMed
  7. ↵
    Eklof AC, Holtback U, Svennilson J, Fienberg A, Greengard P, Aperia A. Increased blood pressure and loss of ANP-induced natriuresis in mice lacking DARPP-32 gene. Clin Exp Hypertension. 2001; 23: 449–460.
    OpenUrl
  8. ↵
    Fedorova OV, Dorofeeva NA, Lopatin DA, Lakatta EG, Bagrov AY. Phorbol diacetate potentiates Na+-K+ ATPase inhibition by a putative endogenous ligand, marinobufagenin. Hypertension. 2002; 39: 298–302.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    William M, Vien J, Hamilton E, Garcia A, Bundgaard H, Clarke RJ, Rasmussen HH. The nitric oxide donor sodium nitroprusside stimulates the Na+-K+ pump in isolated rabbit cardiac myocytes. J Physiol. 2005; 565: 815–825.
    OpenUrlCrossRefPubMed
  10. ↵
    Therien AG, Blostein R. Mechanisms of sodium pump regulation. Am J Physiol Cell Physiol. 2000; 279: C541–C566.
    OpenUrlAbstract/FREE Full Text
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Hypertension
December 2006, Volume 48, Issue 6
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    Atrial Peptides Modify the Effect of Marinobufagenin on Sodium Pumps
    Vardaman M. Buckalew
    Hypertension. 2006;48:1029-1030, originally published November 16, 2006
    https://doi.org/10.1161/01.HYP.0000248119.54493.18

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Hypertension.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Atrial Peptides Modify the Effect of Marinobufagenin on Sodium Pumps
    (Your Name) has sent you a message from Hypertension
    (Your Name) thought you would like to see the Hypertension web site.
  • Share on Social Media
    Atrial Peptides Modify the Effect of Marinobufagenin on Sodium Pumps
    Vardaman M. Buckalew
    Hypertension. 2006;48:1029-1030, originally published November 16, 2006
    https://doi.org/10.1161/01.HYP.0000248119.54493.18
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Cardiology
    • Etiology
      • Hypertension
        • Hypertension
  • Basic, Translational, and Clinical Research
    • Vascular Biology
    • Animal Models of Human Disease

Hypertension

  • About Hypertension
  • Instructions for Authors
  • AHA CME
  • Guidelines and Statements
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
7272 Greenville Ave.
Dallas, TX 75231
email: hypertension@heart.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured